MASLD (fatty liver disease): the Australian general practice approach

Fatty liver disease — now correctly termed MASLD — sits at the intersection of the metabolic syndrome epidemic and the most common chronic liver disease in Australia. Around 30% of Australian adults have hepatic steatosis, but most have no symptoms, no abnormal liver function, and no awareness of the diagnosis. The condition surfaces as an incidental finding on abdominal ultrasound done for another reason, or through an unexplained mild elevation in ALT or GGT.

The 2023 renaming from NAFLD to MASLD (metabolic dysfunction-associated steatotic liver disease) reflects a fundamental repositioning: this is a metabolic disease of the liver, driven by the same cardiometabolic milieu that produces type 2 diabetes, hypertension, and dyslipidaemia. The Rinella et al. multisociety consensus (Hepatology 2023) formalised the new terminology. MASH replaces NASH; MetALD describes MASLD with significant alcohol co-exposure; SLD is the new umbrella.

The most important clinical reorientation: the leading cause of death in MASLD is cardiovascular disease, not liver disease. Treating this as a “liver problem” while neglecting cardiovascular risk is a clinical error. Most people with MASLD die of heart attack or stroke, not cirrhosis.

A. Core clinical — the AU general-practice framework

Definition

MASLD requires two elements: hepatic steatosis on imaging or biopsy, plus at least one cardiometabolic risk factor:

• BMI ≥25 (≥23 in Asian-ancestry populations) or waist circumference above sex- and ethnicity-specific thresholds
• Fasting glucose ≥5.6 mmol/L, HbA1c ≥5.7%, or treated type 2 diabetes
• Blood pressure ≥130/85 or antihypertensive treatment
• Triglycerides ≥1.7 mmol/L or lipid-lowering treatment
• HDL ≤1.0 mmol/L in men or ≤1.3 mmol/L in women, or lipid-lowering treatment

MetALD = MASLD plus significant alcohol intake (>210 g/week in men, >140 g/week in women). MASH = active hepatic inflammation with hepatocyte injury and steatosis, with or without fibrosis.

Who to screen

Consider liver disease assessment in people with: unexplained ALT elevation; incidental fatty liver on imaging; type 2 diabetes (50–70% prevalence); obesity or metabolic syndrome; polycystic ovary syndrome; obstructive sleep apnoea; or unexplained fatigue or right upper quadrant discomfort.

Investigations

Baseline bloods: ALT, AST, GGT, ALP, albumin, bilirubin, INR (synthetic function); FBC with platelets; lipid profile; HbA1c and fasting glucose; ferritin and transferrin saturation (to exclude hereditary haemochromatosis — high ferritin is common in MASLD without iron overload); HBsAg and anti-HCV (hepatitis B and C exclusion); TSH; UEC and eGFR.

Non-invasive fibrosis staging: The Gastroenterological Society of Australia (GESA) recommends the FIB-4 score as the first-line fibrosis assessment tool in general practice:

FIB-4 = (Age × AST) ÷ (Platelet count × √ALT)

• FIB-4 below 1.30 — low fibrosis risk; reassure, lifestyle support, repeat two to three yearly
• FIB-4 1.30–2.67 — indeterminate; FibroScan or hepatology referral
• FIB-4 above 2.67 — high fibrosis risk; hepatology referral
• In adults ≥65, the low-risk threshold adjusts to below 2.0

FibroScan (transient elastography): liver stiffness measurement in kPa. Below 8 kPa indicates likely no significant fibrosis; 8–12 kPa significant fibrosis possible; above 12 kPa advanced fibrosis likely; ≥15–20 kPa cirrhosis range. The CAP score simultaneously quantifies hepatic steatosis.

Liver ultrasound: first-line imaging; detects steatosis with ~80% sensitivity. CT often reveals fatty liver incidentally. MRI is more sensitive but reserved for specific clinical indications.

Liver biopsy: reserve for atypical presentations, suspected coexisting disease, or specialist-directed scenarios. Do not perform routinely.

Cardiovascular risk

Assess and quantify cardiovascular risk at every management review. Aggressive treatment of all modifiable cardiovascular risk factors — LDL-C, blood pressure, glycaemia, smoking — is as important as liver-specific management. The Australian cardiovascular risk calculator should be used at baseline and annually.

B. Non-invasive fibrosis risk stratification and staging

Understanding fibrosis stage is the key GP decision point: it determines the intensity of follow-up, the urgency of specialist referral, and the surveillance requirements.

The FIB-4 pathway

The FIB-4 is free, calculated from routine bloods, and validated across multiple cohorts. NICE NG49 endorses a similar two-step algorithm. In Australian general practice, the FIB-4 replaced the NAFLD Fibrosis Score as the recommended first-line tool following GESA and EASL-EASD-EASO guidance.

A FIB-4 below 1.30 identifies the majority of people as low risk — these patients need lifestyle support, cardiovascular risk management, and repeat assessment every two to three years. They do not need FibroScan or specialist referral routinely.

An indeterminate or high FIB-4 warrants FibroScan for a quantitative liver stiffness measurement. FibroScan is increasingly available in hepatology clinics at public hospitals and in some private radiology practices with GP-direct access.

Advanced fibrosis and cirrhosis

People with F2 or greater fibrosis (FibroScan ≥8 kPa or high FIB-4) require hepatologist review. Those with cirrhosis (F4, FibroScan ≥15 kPa) need: six-monthly liver ultrasound ± AFP for hepatocellular carcinoma surveillance; gastroscopy for variceal assessment at diagnosis; hepatic function monitoring; and consideration of liver transplant listing if decompensation develops.

Hepatocellular carcinoma surveillance

Hepatocellular carcinoma surveillance with six-monthly liver ultrasound and AFP is recommended for all people with cirrhosis regardless of aetiology. Non-cirrhotic MASLD does not routinely warrant HCC surveillance, though high-risk subgroups are under active research.

C. Treatment — weight loss, lifestyle, and emerging pharmacotherapy

Weight loss: the non-negotiable cornerstone

The EASL-EASD-EASO 2024 MASLD Clinical Practice Guidelines confirm that weight loss is the most effective available treatment for MASLD and MASH across all fibrosis stages:

• 5% weight loss reduces hepatic steatosis
• 7% weight loss improves MASH histology (active inflammation)
• ≥10% weight loss can reverse hepatic fibrosis in a meaningful proportion of people

Set these as explicit, progressive targets in the consultation.

Mediterranean diet

The Mediterranean dietary pattern — rich in fish, olive oil, nuts, vegetables, legumes, whole grains, and fruit; low in ultra-processed foods, sugar-sweetened beverages, and fructose — is the best-evidenced dietary approach for MASLD, with benefits extending to cardiovascular risk and glycaemic control. The Australian Liver Foundation provides patient-facing resources on dietary modification.

Exercise prescription

At least 150 minutes per week of moderate aerobic exercise, plus two sessions of resistance training, is recommended. Aerobic exercise reduces hepatic steatosis independently of weight loss. Resistance training provides additional independent benefit. Exercise physiologists are accessible via GPCCMP allied health referral (MBS item 10968).

Alcohol

The safest alcohol intake in MASLD is zero or as close to zero as achievable. For people with MetALD (MASLD plus significant alcohol co-exposure), addressing alcohol is a clinical priority equal to the liver disease itself. Standard drinking limits (below 14 standard drinks per week for men, below 7 for women) are targets for harm reduction, not safe-use endorsements.

Pharmacotherapy

Statins are safe and should not be withheld. This is a well-established clinical principle confirmed by GESA, EASL, and eTG. Mildly elevated transaminases do not contraindicate statins; the cardiovascular benefit in MASLD patients is substantial and the hepatotoxicity risk at therapeutic doses is very low. Check LFTs at baseline and six to twelve weeks — if ALT rises above three times the upper limit of normal, specialist review is appropriate.

GLP-1 receptor agonists: semaglutide and tirzepatide produce substantial weight loss and metabolic improvement relevant to MASLD. Phase 3 MASH trial data for semaglutide 2.4 mg weekly are promising. In Australia, semaglutide 1 mg (Ozempic) is PBS Authority-funded for type 2 diabetes; semaglutide 2.4 mg (Wegovy) is TGA-registered for obesity but not PBS-listed as of mid-2026.

Resmetirom (Rezdiffra): the MAESTRO-NASH phase 3 trial (NEJM 2024) demonstrated significant MASH resolution and fibrosis improvement. FDA-approved in the United States in March 2024. Not TGA-approved or PBS-listed in Australia as of mid-2026; accessible only via Special Access Scheme at high private cost.

Pioglitazone: improves MASH histology in biopsy-proven MASH. Off-label for MASLD; PBS Authority for type 2 diabetes. Weight gain, fluid retention, and fracture risk in women are limiting side effects.

Vitamin E: the PIVENS trial demonstrated modest histological benefit in biopsy-proven MASH in non-diabetic adults. Long-term safety concerns limit routine use. Not recommended in people with diabetes or cirrhosis.

Bariatric surgery: the most effective intervention for MASLD — sleeve gastrectomy and gastric bypass resolve MASH histologically in the majority of patients and reduce fibrosis. Typical Australian eligibility: BMI ≥35 plus metabolic comorbidity. Public access is limited; private surgery or health fund cover is the predominant pathway.

SGLT2 inhibitors: modest hepatic steatosis reduction with compelling cardiovascular and renal benefits in type 2 diabetes plus MASLD.

Metformin: safe; first-line for type 2 diabetes; modest weight loss benefit. Does not have specific MASLD or MASH efficacy data.

D. Australian operations

MBS items

• Items 23, 36, 44 — GP consultations
• Item 965 / 967 — GPCCMP for chronic care planning in MASLD with comorbidities
• Item 715 — ATSI Health Assessment including metabolic screen
• Item 707 — 75+ Health Assessment
• Item 55028 / 55036 — liver / abdominal ultrasound
• Item 10954 — accredited dietitian under EPC / GPCCMP
• Item 10968 — exercise physiologist under EPC
• Item 132 / 133 — consultant physician (gastroenterology / hepatology) initial / subsequent review

PBS prescribing

Statins: rosuvastatin and atorvastatin are General Schedule for most indications. Metformin: General Schedule. GLP-1 RA (semaglutide 1 mg, dulaglutide, liraglutide): Authority for type 2 diabetes under specific criteria. Wegovy 2.4 mg: TGA-registered for obesity but not PBS-funded. Tirzepatide (Mounjaro): Authority for type 2 diabetes. SGLT2 inhibitors (empagliflozin, dapagliflozin): Authority for type 2 diabetes with cardiovascular or renal comorbidity. Check PBS Online for current criteria.

Vaccinations

People with MASLD, especially those with advanced fibrosis, should be offered hepatitis A and hepatitis B vaccination if non-immune, plus standard age-appropriate vaccines (pneumococcal, influenza, COVID-19, shingles if eligible).

Referral pathways

Refer to hepatology or gastroenterology when: FIB-4 is indeterminate or high; FibroScan ≥8 kPa; atypical features or suspected coexisting liver disease; decompensated cirrhosis at any FIB-4 level. Refer to bariatric surgery when BMI ≥35 with metabolic comorbidity and lifestyle interventions have been inadequate.

E. Special populations

Type 2 diabetes. MASLD prevalence reaches 50–70% in people with type 2 diabetes. Optimise glycaemia through the metabolic lens — GLP-1 RA and SGLT2i have both metabolic and hepatic benefits and are preferred add-on therapies when lifestyle alone is insufficient.

Polycystic ovary syndrome (PCOS). MASLD is significantly more prevalent in women with PCOS due to shared insulin resistance. Screen with FIB-4 and liver ultrasound. Address both conditions through weight management, metabolic optimisation, and hormonal regulation.

Pregnancy. MASLD in pregnancy is associated with gestational diabetes and pre-eclampsia. Manage through dietary optimisation and surveillance of metabolic parameters. Most pharmacotherapy is contraindicated; lifestyle remains the primary tool.

Older adults. The FIB-4 low-risk threshold adjusts to below 2.0 in adults aged ≥65, as AST normally rises with age and the standard threshold over-triggers specialist referral. Apply the age-adjusted cut-off to reduce unnecessary investigations.

ATSI Australians. Higher rates of type 2 diabetes, metabolic syndrome, and alcohol-related liver disease in First Nations communities make MASLD screening and cardiovascular risk reduction a priority within the ATSI Health Assessment framework.

When to escalate

Escalate to hepatology or gastroenterology when:

• FIB-4 is indeterminate (1.30–2.67) or high (>2.67)
• FibroScan ≥8 kPa or liver stiffness in the significant fibrosis range
• Cirrhosis features — low platelet count, abnormal synthetic function (raised INR, low albumin, raised bilirubin), clinical evidence of portal hypertension
• Suspected hepatocellular carcinoma — new hepatic lesion in a person with cirrhosis or risk factors
• Decompensated cirrhosis — ascites, encephalopathy, variceal haemorrhage
• Atypical features — rapid transaminase rise, suspected autoimmune hepatitis, haemochromatosis, Wilson’s disease

Escalate to bariatric surgery when BMI ≥35 with metabolic comorbidity and lifestyle plus pharmacotherapy have not achieved sustained weight loss.

What this article is and is not

This is general health information drawn from current Australian and international guidelines — GESA liver disease guidance, eTG Gastrointestinal, NICE NG49, and the EASL-EASD-EASO 2024 MASLD guidelines. It is not personal medical advice and does not create a doctor–patient relationship. Assessment of fibrosis stage, management of MASH, and prescribing decisions require assessment by the treating GP in the context of individual clinical circumstances.

For consumer information: Australian Liver Foundation, HealthDirect — Fatty liver disease, Better Health Channel.

---

Sources cited

1. Gastroenterological Society of Australia (GESA)
2. Australian Liver Foundation
3. Therapeutic Guidelines (eTG) — Gastrointestinal
4. RACGP
5. NICE NG49 — NAFLD assessment and management
6. Rinella ME et al. — MASLD nomenclature consensus (Hepatology 2023)
7. Anstee QM et al. — MAESTRO-NASH phase 3 trial (NEJM 2024)
8. EASL-EASD-EASO 2024 MASLD Clinical Practice Guidelines
9. HealthDirect — Fatty liver disease
10. Better Health Channel — Fatty liver disease
11. TGA
12. PBS